ABSTRACT
Given the close interpersonal nature of the student-clinical instructor (CI) relationship and the unpredictable and often stressful clinical environment in which they interact with one another, it is extremely important that CIs understand how their behavior directly affects their students' motivation to engage in educationally important clinical activities. This article presents a review of the motivation literature grounded in self-determination theory with the goal of providing the reader insight into how CI psychologic need-supporting/thwarting behaviors affect student-CI engagement. Specific need-supporting and need-thwarting behaviors are identified and discussed in terms of how they impact students' needs for autonomy, competency, and relatedness. Recent research has revealed a strong connection between overall CI need-supporting/thwarting behavior and student clinical engagement. The author hopes to bring further awareness of the powerful psychologic impact CIs have on their students and to draw attention to the need for routine in-service programs specifically designed to teach CIs how to effectively use psychologic need-supporting behaviors and avoid psychologic need-thwarting behaviors when working with their students.
Subject(s)
Education, Medical , Motivation , Students/psychology , Humans , Nuclear Medicine/educationABSTRACT
Current literature supports outpatient parenteral antimicrobial therapy (OPAT). This article presents results from a research study that evaluated an OPAT program that treated community-acquired pneumonia. If patients had the opportunity to receive outpatient intravenous antibiotics for community-acquired pneumonia, would this prevent future hospitalization? Was there a decrease in hospital admissions? An informal cost-benefit analysis comparing OPAT with inpatient hospital admissions for the same disease was also reviewed to provide evidence whether there was a change. What was the overall health care cost savings? The medical charts of 50 patients with confirmed pneumonia who had received OPAT in a 3-month period were reviewed. A retrospective medical record review was performed. All patients were evaluated by the in-house OPAT team. The resulting analysis provided evidence that an estimated savings of approximately $2100 per day would be achieved by decreasing hospital readmissions for patient who had been treated with OPAT. The conclusion of this study provides evidence that the implement of an OPAT program was, and is, essential for patient care and evidence-based best practice adherence.
Subject(s)
Ambulatory Care , Anti-Infective Agents/therapeutic use , Hospitals, Rural , Infusions, Parenteral/methods , Cost-Benefit Analysis/economics , Humans , Infusions, Intravenous , Patient Readmission , Retrospective StudiesABSTRACT
A series of N(6)-bicyclic and N(6)-(2-hydroxy)cyclopentyl derivatives of adenosine were synthesized as novel A1R agonists and their A1R/A2R selectivity assessed using a simple yeast screening platform. We observed that the most selective, high potency ligands were achieved through N(6)-adamantyl substitution in combination with 5'-N-ethylcarboxamido or 5'-hydroxymethyl groups. In addition, we determined that 5'-(2-fluoro)thiophenyl derivatives all failed to generate a signaling response despite showing an interaction with the A1R. Some selected compounds were also tested on A1R and A3R in mammalian cells revealing that four of them are entirely A1R-selective agonists. By using in silico homology modeling and ligand docking, we provide insight into their mechanisms of recognition and activation of the A1R. We believe that given the broad tissue distribution, but contrasting signaling profiles, of adenosine receptor subtypes, these compounds might have therapeutic potential.
Subject(s)
Bridged Bicyclo Compounds, Heterocyclic/pharmacology , Cyclopentanes/pharmacology , Drug Discovery , Purinergic P1 Receptor Agonists/pharmacology , Adenosine/chemistry , Adenosine/pharmacology , Bridged Bicyclo Compounds, Heterocyclic/chemical synthesis , Bridged Bicyclo Compounds, Heterocyclic/chemistry , Cyclopentanes/chemical synthesis , Cyclopentanes/chemistry , Dose-Response Relationship, Drug , Humans , Molecular Structure , Purinergic P1 Receptor Agonists/chemical synthesis , Purinergic P1 Receptor Agonists/chemistry , Receptor, Adenosine A1/metabolism , Receptor, Adenosine A3/metabolism , Structure-Activity Relationship , Substrate Specificity/drug effectsABSTRACT
Producer reports from ranches over 2,438 meters in southwest Colorado suggest that the mortality of preweaned beef calves may be substantially higher than the national average despite the selection of low pulmonary pressure herd sires for over 20 years. Diagnostic investigations of this death loss problem have been limited due to the extensive mountainous terrain over which these calves are grazed with their dams. The objective of the current study was to determine the causes of calf mortality on 5 high-altitude ranches in Colorado that have been selectively breeding sires with low pulmonary pressure (<45 mmHg) for over 20 years. Calves were followed from branding (6 weeks of age) in the spring to weaning in the fall (7 months of age). Clinical signs were recorded, and blood samples were taken from sick calves. Postmortem examinations were performed, and select tissue samples were submitted for aerobic culture and/or histopathology. On the principal study ranch, 9.6% (59/612) of the calves that were branded in the spring either died or were presumed dead by weaning in the fall. In total, 28 necropsies were performed: 14 calves (50%) had lesions consistent with pulmonary hypertension and right-sided heart failure, and 14 calves (50%) died from bronchopneumonia. Remodeling of the pulmonary arterial system, indicative of pulmonary hypertension, was evident in the former and to varying degrees in the latter. There is a need to better characterize the additional risk factors that complicate pulmonary arterial pressure testing of herd sires as a strategy to control pulmonary hypertension.
Subject(s)
Altitude , Blood Pressure/physiology , Cattle Diseases/pathology , Hypertension, Pulmonary/veterinary , Lung/blood supply , Animals , Breeding , Cattle , Cattle Diseases/genetics , Female , Genetic Predisposition to Disease , Hypertension, Pulmonary/genetics , Hypertension, Pulmonary/pathology , Longevity , Male , Risk FactorsABSTRACT
We herein report the discovery of a novel class of antagonists of the human adenosine A2B receptor. This low molecular weight scaffold has been optimized to offer derivatives with potential utility for the alleviation of conditions associated with this receptor subtype, such as nociception, diabetes, asthma and COPD. Furthermore, preliminary pharmacokinetic analysis has revealed compounds with profiles suitable for either inhaled or systemic routes of administration.
Subject(s)
Adenosine A2 Receptor Antagonists , Pyrimidines/chemistry , Administration, Inhalation , Animals , Asthma/drug therapy , Drug Design , Humans , Pulmonary Disease, Chronic Obstructive/drug therapy , Pyrimidines/chemical synthesis , Pyrimidines/pharmacokinetics , Rats , Receptor, Adenosine A2A/metabolism , Receptor, Adenosine A2B/metabolismABSTRACT
Antagonism of the human A(2A) receptor has been implicated as a point of therapeutic intervention in the alleviation of the symptoms associated with Parkinson's disease. This is thought to occur, at least in part, by increasing the sensitivity of the dopaminergic neurons to the residual, depleted levels of striatal dopamine. We herein describe a novel series of functionalized triazolo[4,5-d]pyrimidine derivatives that display functional antagonism of the A(2A) receptor. Optimization of these compounds has resulted in improvements in potency, selectivity, and the pharmacokinetic properties of key derivatives. These efforts have led to the discovery of 60 (V2006/BIIB014), which demonstrates strong oral activity in commonly used models of Parkinson's disease. Furthermore, this derivative has shown excellent preclinical pharmacokinetics and has successfully completed phase I clinical studies. This compound is presently undergoing further clinical evaluation in collaboration with Biogen Idec.
Subject(s)
Adenosine A2 Receptor Antagonists , Azoles/chemical synthesis , Azoles/pharmacology , Drug Design , Pyrimidines/chemical synthesis , Pyrimidines/pharmacology , Amines/chemistry , Animals , Azoles/chemistry , Azoles/therapeutic use , Drug Evaluation, Preclinical , Gait Disorders, Neurologic/chemically induced , Gait Disorders, Neurologic/drug therapy , Haloperidol/pharmacology , Humans , Mice , Molecular Structure , Pyrimidines/chemistry , Pyrimidines/therapeutic use , Rats , Receptor, Adenosine A2A/classification , Receptor, Adenosine A2A/metabolism , Structure-Activity RelationshipABSTRACT
OBJECTIVE: To describe the prevalence of West Nile virus (WNV) infection and evaluate factors associated with positive IgM capture ELISA results in equids with clinical signs compatible with WNV infection. DESIGN: Retrospective case series. SAMPLE POPULATION: Laboratory submission forms from 1,104 equids tested for WNV in Colorado in 2003. PROCEDURES: Submission forms accompanying samples submitted for detection of WNV via IgM capture ELISA were obtained from the Colorado state veterinarian and diagnostic laboratories performing the tests. Data on signalment, clinical signs, history of vaccination against WNV, and assay results were collected from laboratory submission forms. Equids with clinical signs compatible with WNV infection in which IgM capture ELISA results were positive were considered as case equids. RESULTS: 1,104 equids were tested for WNV; 1,017 (92.1%) had clinical signs compatible with WNV infection. Among equids with clinical signs compatible with WNV infection, the odds of testing positive for WNV via IgM capture ELISA were lower in males and in vaccinated equids and higher in equids with moderate and severe illness, compared with females, unvaccinated equids, and equids with mild illness. CONCLUSIONS AND CLINICAL RELEVANCE: Among equids with clinical signs compatible with WNV infection, vaccination against WNV, severity of clinical signs, duration of illness, and region in Colorado were associated with increased risk of having a positive IgM capture ELISA result.